Identifying patients at risk of lung disease after tuberculosis treatment
Identifying patients at risk of post-tuberculosis lung disease using novel cough and adherence predictors
This study is looking for ways to help people who have finished their tuberculosis treatment by finding out who might develop lung problems later on, using new tools like a mobile app to track coughs instead of just relying on standard lung tests.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10891638 on NIH RePORTER |
What this research studies
This research investigates how to identify patients who are at risk of developing post-tuberculosis lung disease (PTLD) after completing their TB treatment. It aims to use innovative methods, such as monitoring cough frequency and using a mobile app to analyze cough sounds, as alternatives to traditional lung function tests that may not be available in many regions. By understanding patient adherence to treatment and changes in cough patterns, the study seeks to improve early detection and intervention for those at risk of PTLD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently completed treatment for tuberculosis and may be experiencing respiratory symptoms.
Not a fit: Patients who have not been treated for tuberculosis or those with pre-existing chronic lung diseases unrelated to TB may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better early identification and management of patients at risk for post-tuberculosis lung disease, potentially improving their long-term health outcomes.
How similar studies have performed: Other research has shown promise in using mobile health technologies for monitoring respiratory conditions, indicating that this approach may be effective.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Huddart, Sophie — University of California, San Francisco
- Study coordinator: Huddart, Sophie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.